Personalized Bone Organoids from iPSC-Derived Cells
Author Information
Author(s): Gao Qi, Teissier Victoria, Zhu Wenjuan, Makarcyzk Meagan J, Shinohara Issei, Murayama Masatoshi, Susuki Yosuke, Chow Simon Kwoon-Ho, Bunnell Bruce A., Wu Joy, Lin Hang, Goodman Stuart B.
Primary Institution: Stanford University School of Medicine
Hypothesis
iMPCs, iECs, and iMØs would display heterogeneous phenotypes that are dependent on the host’s biological capacities.
Conclusion
The study suggests that iPSC-derived cells can be used to anticipate the effectiveness of cell-based therapies for personalized tissue regeneration.
Supporting Evidence
- Cells from different donors exhibited patient-specific characteristics and different regenerative capacities.
- iMPCs shared many similarities but showed different trilineage differentiable abilities.
- iPSC-derived ECs can be used for vascular development without significant heterogeneity.
- iMØs exhibited a high degree of similarity to primary macrophages.
Takeaway
Scientists created special cells from patients' own stem cells to help understand how to heal bones better for each person.
Methodology
The study involved generating iPSC-derived mesenchymal progenitor cells, endothelial cells, and macrophages from different donors and co-culturing them in a 3D model to study bone regeneration.
Potential Biases
Cell characteristics may change due to underlying medical comorbidities, medications, and culture conditions.
Limitations
Only four lines of iPSCs were used, which may not represent the full variability in patient responses.
Participant Demographics
Two iPSC lines from healthy donors and two from patients with cardiovascular disease.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website